Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Enumeral, Merck in Immune Profiling Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Enumeral, Merck in Immune Profiling Pact

Aims to identify cellular responses for oncology immunotherapies

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Enumeral Biomedical Holdings, Inc. and Merck, through a subsidiary, have signed an oncology collaboration study agreement to use Enumeral’s human approach in colorectal cancer tissues from patients to identify cellular responses to immune-oncology therapies being developed by Merck.
 
Enumeral’s immune profiling platform may increase the probability of finding rare immune cells associated with disease or drug response through improved efficiency and sensitivity. Enumeral will receive R&D funding and is eligible to receive undisclosed milestone payments if certain goals are met. Merck has exclusive rights to data related to its compounds that are generated from the studies.
 
“Our platform provides the opportunity to understand broadly how immunotherapy works in humans, based on its ability to evaluate the function of critical rare immune cells in human clinical samples,” said Arthur H. Tinkelenberg, Ph.D., president and chief executive officer of Enumeral. “The ability to determine cellular functions within these samples, we believe, has the potential to accelerate discovery and development of immunotherapies in oncology. We are very pleased to be working with Merck, one of the leaders in the field of antibody immunotherapy, to tackle these important clinical problems.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics